March 26(Reuters) - RaQualia Pharma Inc
* Says it and Asahi Kasei Pharma Corp have entered into a license agreement for a novel P2X7 receptor antagonist discovered through a research collaboration between the two companies
Source text in Japanese:goo.gl/TJ8sZH
Further company coverage: (Beijing Headline News)